drugset / Trial / NCT04462952
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
Non-randomizedSingle-groupOpen-labelOther
Summary
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours. This study consists of 2 parts, monotherapy (part A) and chemotherapy combination (part B). At least 3, or up to 6, evaluable Japanese patients with advanced solid tumours will be enrolled in each cohort to confirm the tolerability.
Timeline
- Start
- 2020-06-24
- Primary completion
- 2021-09-22
- Completion
- 2021-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 200 mg | Oral |
| Subject | Adavosertib | Small molecule | 250 mg | Oral |